Details
Immunotherapy
Advances in Experimental Medicine and Biology, Band 995 2nd ed. 2018
|
85,59 € |
|
| Verlag: | Springer |
| Format: | |
| Veröffentl.: | 11.12.2018 |
| ISBN/EAN: | 9783030025052 |
| Sprache: | englisch |
Dieses eBook enthält ein Wasserzeichen.
Beschreibungen
<p>The second edition of <i>Immunotherapy </i>is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. </p>
<p>This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions.</p>
Edited by two renowned experts in the field, the book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
<p>This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions.</p>
Edited by two renowned experts in the field, the book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
<p>Overview of Basic Immunology and Translational Relevance for Clinical Investigators.- Immunotherapy for Melanoma.- Immunotherapy in Lung Cancer: A New Age in cancer treatment.- Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.- Skin Reactions to Immune Checkpoint Inhibitors.- Immune-related Adverse Events: Pneumonitis.- Immune checkpoint inhibitors-induced colitis.- Immune checkpoint inhibitors-induced hepatitis.- Symptoms as patient-reported outcomes in cancer patients undergoing immunotherapies .</p><p><br></p><p><br></p>
<b>Dr. Aung Naing</b> is an Associate Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing’s research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.<br><div><p><b>Joud Hajjar</b> is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children’s Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Early Career Immunologist Committee at the Clinical Immunology Society.</p> <p>Dr. Hajjar serves as a reviewer for the <i>Journal of Clinical Immunology</i>, <i>Journal of General Internal Medicine</i> and <i>Allergy and Asthma Proceedings</i>. She has received travel awards to present her research at the Clinical Immunology Society, American Academy of Allergy, Asthma and Immunology, and the American College of Allergy, Asthma and Immunology national meetings.</p> <p>Dr. Hajjar's research interests are in primary immunodeficiency disorders, and cancer immunotherapy.</p></div>
<p>The second edition of <i>Immunotherapy </i>is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. </p>
<p>This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions.</p>
Edited by two renowned experts in the field, the book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
<p>This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions.</p>
Edited by two renowned experts in the field, the book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
Highlights the significant developments in the field of immuno-oncology to inform the scientific community Summarizes diverse immunotherapeutic approaches for management of cancer to update professionals with the latest Describes biomarker strategies to identify patients who are likely to respond to immunotherapy narrates Outlines strategies to overcome challenges associated with immunotherapies: distinguish pseudoprogression from progressive disease, immune-related adverse events
Diese Produkte könnten Sie auch interessieren:
